Methodology comparison and influence factors analysis of epidermal growth factor receptor mutation detection

National Medical Journal of China

Volumn 95, Issue 2, 2015, Pages 106-111

  Xiaoxan, Qian ^a   Shuai, Wang ^a   Yinrhen, Shen ^a   Di, Wu ^a   Zhishang, Zhang ^a   Yuri, Feng ^a   Xianhong, Han ^a   Yuankai, Shi ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Direct sequencing; Epidermal growth factor receptor; Gene mutation; Lung neoplasms; Scorpions amplification refractory mutation system

Indexed keywords

DNA;

ADVANCED CANCER; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; DNA EXTRACTION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; NON SMALL CELL LUNG CANCER;

EID: 84922478691     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2015.02.007     Document Type: Article

References (21)

1. Lrmer D, Furik JO, Blaukat A. EGKR kinase domain mulalions- functional impac't and relevance for lung cancel' therapy [ J ]. Oncogene, 2007, 26(39) : 5693-5701.
2. Dutta PR, Maity A. Cellular responses to EGKR inhibitors and their relevance to cancer therapy [ J ]. Cancer Lett, 2007, 254( 2 ) : 165-177.
3. Yatabe Y. EGKR mutations and the terminal respiratory unit [ J ] - Cancer Metastasis Rev, 2010, 29( 1 ) :23-36.
4. Shi Y, Au J S K, Thongprasert S, et al. A Prospective, Molecular- Epidemiology Study of EGKR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) [J]. J Thorac Oncol, 2014, 9 ( 2 ) : 154- 162.
5. Keedy V L, Temin S, Somerfield M R, et al. American Society ol Clinical Oncology provisional clinical opinion; Epidermal growth factor receptor ( EGER ) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGKR tyrosine kinase inhibitor therapy [ J ]. J Clin Oncol, 2011, 29 ( 15) :2121-2127.
6. Giaccone G, Rajan A, Bernian A, et al. Phase II study ol belinostat in patients with recurrent or refractory advanced thymic epithelial tumors[J]. J Clin Oncol, 2011, 29 ( 15 ) :2052-2059.
7. Paez JG, Jarine PA, Lee JC, et al. EGKR mutations in lung cancer; correlation with clinical response to gelitinib therapv[J] . Science, 2004, 304(5676) : 1497-1500.
8. Jänne PA., Johnson RE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor hrosine kinase inhibitors[J]. Clin Cancer Res, 2006, 12 (14 Suppl) :4416s-4420s.
9. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously frealed advanced non-small-cell lung cancer ( 1C0GEN ); a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10);953-961.
10. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy [J] . Eur J Cancer, 2006, 42(1) : 17-23.
11. Ellison G, Donald E, McWaller G, et al. A comparison of ARMS and DNA sequencing lor mutation analysis in clinical biopsy samples [J] . J Exp Clin Cancer Res, 2010, 29 ( 1 ) : 132.
12. Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences arid redefines the sensitivity of genetic lesling [J]. Nat Med, 2008, 14(5) :579-584.
13. Sharma SV, Bell DV, Settleman J, et al. Epidermal growth factor receptor mutations in lung caricer[J]. Nat Rev Cancer, 2007, 7 (3) :169-181.
14. Le Maignan L, Mirebeau-Prunier D, Vervueren L, et al. First case of A859T epidermal growth factor receptor mutation responding to erlotinih [J], J Thorac Oncol, 2011, 6(3) : 639-640.
15. Costa DB, Schumer ST, Tenen DG, et al. Differential responses to erlotinib in epidermal growth factor receptor ( EGKR) -mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations[J]. J Clin Oncol, 2008, 26 (7) : 1182-1184.
16. Han Y, Park K, Kim SW, et al. Kirst-SIGNAL; first-line single- agent iressa versus gemeitabine and eisplatin trial in never-smokers with adenocarcinoma ol the lung [J], J Clin Oneoi, 2012, 30 ( 10) :1122-1128.
17. FukuokaM, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplalin/paelitaxel in clinically selected patients with advanced non-small- cell lung cancer in Asia (IPASS) [J].. J Clin Oncol, 2011, 29 (21) :2866-2874.
18. Mok TS, Wu YL, Thongprasert S.et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma [J]. N Engl j Med, 2009, 361(10) :947-957.
19. Maemondo M, Inoue A, Kobayashi KI, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGKR [J ]. N Engl J Med, 2010, 362(25) :2380-2388.
20. Rivero ERC, Neves AC, Silva-Valenzuela MG, et al. Simple salting-out method lor DNA extraction from formalin-fixed, paraffin-embedded tissues[J]. Pathol Res Pract, 2006, 202 ( 7 ) : 523-529.
21. Whyte B. National tumor bank set up in United Kingdom [ J ]. J Natl Cancer Inst, 2003, 95 ( 10 ) :706.